Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab for cancer pain due to bone metastasis in patients on background opioid therapy
2013-002223-42Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer pain and bone metastases comparing Tanezumab 20 mg subcutaneous with Placebo subcutaneous (2 arms). Primary endpoint: Change from baseline to Week 8 in daily average pain intensity at the index bone metastasis cancer pain site. Started Sep 2015; status: completed.
02
Drugs
tanezumab
03
Conditions
cancer painbone metastases
Beyond the preview
Go deeper on 2013-002223-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002223-42.